Maintenance Therapy for Ovarian Cancer: Of Helsinki and Hippocrates-Reference-Cited by-同舟云学术

Maintenance Therapy for Ovarian Cancer: Of Helsinki and Hippocrates

Published:2009-10-01 Issue:28 Volume:27 Page:4633-4634
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

McGuire William Patrick¹

Affiliation:

1. Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center, Baltimore, MD

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2009.23.6653

Reference8 articles.

1. Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1

2. Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

3. Regulations and ethical guidelines: World Medical Association Declaration of Helsinki National Institutes of Health: Office of Human Subjects Research http://ohsr.od.nih.gov/guidelines/helsinki.html

4. The Ethics of Early Stopping Rules: Who Is Protecting Whom?

5. Pretreatment CA-125 and Risk of Relapse in Advanced Ovarian Cancer

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A senescence-like state is beneficial for ovarian cancer treatment;2023-10-02

2. The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers cisplatin resistance in ovarian cancer;Cell Death & Disease;2023-08-26

3. Mitochondria-targeted nanoparticles overcome chemoresistance via downregulating BACH1/CD47 axis in ovarian carcinoma;Chinese Chemical Letters;2023-08

4. The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers chemoresistance in ovarian cancer;2023-02-07

5. Applicability of the Histoculture Drug Response Assay to Predict Platinum Sensitivity and Prognosis in Ovarian Cancer;Anticancer Research;2021-11-30